Chen Tiangui, Li Tianbo, Wang Jiangning
Department of Orthopedics Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, P.R. China.
Oncol Lett. 2021 Nov;22(5):766. doi: 10.3892/ol.2021.13027. Epub 2021 Sep 8.
Osteosarcoma is a common primary bone malignancy, with a 5-year survival rate of only 20-30% in patients undergoing surgical treatment. Thus, it is important to identify novel methods for diagnosing and treating osteosarcoma, which was the aim of the present study. Vascular endothelial growth factor (VEGF) was used as the tumor-targeting protein to synthesize a multifunctional core-shell nanostructure, Au@SiO-drug/VEGF, in which the drug can be indocyanine green (ICG; as an optical tracer) or doxorubicin (DOX; as a chemotherapeutic agent). With VEGF as the osteosarcoma-targeting protein, Au exhibited optimal photothermal transformation performance, while SiO served as the carrier for the drug. Au@SiO-ICG/VEGF nanoparticles (NPs) were evaluated for imaging and for the monitoring of drug accumulation in a tumor region in mice. Once the optimal drug accumulation was achieved, combined treatment of osteosarcoma (chemotherapy and photothermal therapy) was assessed. In the perioperative period associated with minimal invasive embolization of osteosarcoma, photothermal therapy and chemotherapy were applied for osteosarcoma diagnosis using Au@SiO-DOX/VEGF NPs. Taken together, the results of the present study provide a promising strategy for tumor detection prior to surgical treatment to improve the survival outcome of patients with osteosarcoma.
骨肉瘤是一种常见的原发性骨恶性肿瘤，接受手术治疗的患者5年生存率仅为20%-30%。因此，确定诊断和治疗骨肉瘤的新方法很重要，这也是本研究的目的。血管内皮生长因子（VEGF）被用作肿瘤靶向蛋白，以合成一种多功能核壳纳米结构Au@SiO-药物/VEGF，其中药物可以是吲哚菁绿（ICG；作为光学示踪剂）或阿霉素（DOX；作为化疗药物）。以VEGF作为骨肉瘤靶向蛋白，金表现出最佳的光热转换性能，而二氧化硅作为药物载体。评估了Au@SiO-ICG/VEGF纳米颗粒（NPs）在小鼠肿瘤区域的成像和药物蓄积监测。一旦实现最佳药物蓄积，就评估骨肉瘤的联合治疗（化疗和光热疗法）。在与骨肉瘤微创栓塞相关的围手术期，使用Au@SiO-DOX/VEGF NPs对骨肉瘤进行光热疗法和化疗诊断。总之，本研究结果为手术治疗前的肿瘤检测提供了一种有前景的策略，以改善骨肉瘤患者的生存结局。
